abstract |
A composition for use in the treatment of cancer due to GST-π overexpression and KRAS mutation, in which the composition comprises as active ingredients a drug that suppresses GST-π and a drug that suppresses autophagy, in which the autophagy-suppressing drug is a PI3K inhibitor, and wherein the PI3K inhibitor is a class III PI3K inhibitor. |